Evidence map›Paper›PMID 41561441›Full record

ArticleNAR cancer2026

Differential roles of Rad18 in repressing carcinogen- and oncogene-driven mutagenesis

Jay R Anand, Bethany Wagner Brown, Jitong Lou, Qisheng Gu, Yang Yang, Gaith Droby, Di Wu, Akankshya Jena, Jialiu Xie, Yuri Fedoriw and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NAR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Jay R AnandDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.ORCID 0000-0003-2071-9891
Bethany Wagner BrownDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Jitong LouDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Qisheng GuDivision of Oral and Craniofacial Health Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Yang YangDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Gaith DrobyCurriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC 27599, United States.
Di WuDivision of Oral and Craniofacial Health Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.ORCID 0000-0001-8331-2357
Akankshya JenaDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Jialiu XieDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Yuri FedoriwDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Bernard WeissmanDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Scott WilliamsDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.
Cyrus VaziriDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
A Novel Carcinogen-Induced Cell Cycle CheckpointR01ES009558 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAZIRI, CYRUS · 2002 to 2016
$4.8M
Defining Mechanisms of Pathological Trans-Lesion Synthesis During CarcinogenesisR01CA215347 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAZIRI, CYRUS, WILLIAMS, SCOTT E · 2018 to 2022
$2.6M
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic targetR01CA229530 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEARCE, KENNETH HUGH, VAZIRI, CYRUS · 2019 to 2023
$2.0M
Intrinsic and extrinsic spindle orientation mechanisms in mammalian epidermisR01AR077591 · NIAMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WILLIAMS, SCOTT E · 2021 to 2025
$1.6M
NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA215347NCI NIH HHS R01 CA229530NIAMS NIH HHS R01 AR077591NIEHS NIH HHS P30 ES010126NIEHS NIH HHS R01 ES009558
6 · The paper itself

Abstract

The DNA repair protein RAD18 activates "Y-family"

Indexed as

CarcinogensCarcinoma, Squamous CellDNA-Binding ProteinsMouth NeoplasmsMutagenesisOncogenes4-Nitroquinoline-1-oxideAnimalsCarcinogenesisDNA DamageDNA-Directed DNA PolymeraseHumansMiceMice, KnockoutTranslesion DNA SynthesisUbiquitin-Protein Ligases4-Nitroquinoline-1-oxideCarcinogensDNA-Binding ProteinsDNA-Directed DNA PolymeraseRad18 protein, mouseUbiquitin-Protein Ligases

Identifiers

PMID41561441
PMCPMC12813500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.